The perception and management of drug safety risks / edited by Bruno Horisberger, Rolf Dinkel.

Contributor(s): Material type: TextTextLanguage: English Series: Health Systems Research ; 1431-4002Publication details: Berlin, Heidelberg ; New York : Springer Berlin Heidelberg, 1989.Description: xxiii, 210 σ. : εικ., διαγρ., πιν. ; 25 εκISBN:
  • 3540505342
Subject(s): DDC classification:
  • 615.19
Contents:
Opening Address -- I: Society and the Benefit/Risk Relationship -- 1. Acceptable Risk in Society -- 2. A Broad Framework for Confronting Health Risks -- 3. Communicating the Risks and Benefits of Technology: The Case of Pharmaceuticals -- 4. Overview of the Drug Safety Issue and Ciba-Geigy’s Response: RAD-AR -- 5. Summary of Part I: Presentations and Discussions -- II: Benefit/Risk Analysis and Appraisal -- 6. Limitations of Available Sources of Data on Prescription Drug Safety -- 7. Strategies, Designs, Criteria, Tactics and Statistics to be Considered when Evaluating Scientific Evidence -- 8. Statistics in Drug Risk Research: The Background of Pharmacoepidemiology -- 9. Industry-Sponsored Risk Institutes -- 10. The Feldene Experience: A Case Study -- 11. Risk Perception of Prescription Drugs: Report on a Survey in Sweden -- 12. Risk Perception of Prescription Drugs: Report on Surveys in Japan -- 13. Scientific and Political Components of Regulatory Decision Making: General Considerations -- 14. Scientific and Political Components of Regulatory Decision Making: The United States Experience -- 15. Summary of Part II: Presentations and Discussions -- III: Current Challenges -- 16. Professional Drug Information: A Consumer Perspective -- 17. Going Patient, Going Public -- 18. Reporting Adverse Drug Reactions: The Media Approach -- 19. What Can Be Learned from Drug Safety Issues? -- 20. Summary of Part III: Presentations and Discussions -- IV: Responding to the Issues -- 21. Editor’s Note -- 22. Pharmacoepidemiology -- 23. Risk Perception Analysis -- 24. Communicating the Benefit/Risk Relationship -- 25. Risk Appraisal on an International Scale -- V: Outlook -- 26. The Wolfsberg Questions -- VI: Annex -- 27. Curriculum Vitae of Authors -- 28. Bibliography -- 29. Subject Index -- 30. A Handbook of International Data Sources for Drug Benefit/Risk Assessment.
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Call number Copy number Status Date due Barcode
Books Books ΠΑΔΑ 615.19 PER (Browse shelf(Opens below)) 1 Not For Loan 00005359

Περιέχει παράρτημα με τα Βιογραφικά των συγγραφέων, γλωσσαριο και πίνακες.

Βιβλιογραφία : σ.191-201.

Opening Address -- I: Society and the Benefit/Risk Relationship -- 1. Acceptable Risk in Society -- 2. A Broad Framework for Confronting Health Risks -- 3. Communicating the Risks and Benefits of Technology: The Case of Pharmaceuticals -- 4. Overview of the Drug Safety Issue and Ciba-Geigy’s Response: RAD-AR -- 5. Summary of Part I: Presentations and Discussions -- II: Benefit/Risk Analysis and Appraisal -- 6. Limitations of Available Sources of Data on Prescription Drug Safety -- 7. Strategies, Designs, Criteria, Tactics and Statistics to be Considered when Evaluating Scientific Evidence -- 8. Statistics in Drug Risk Research: The Background of Pharmacoepidemiology -- 9. Industry-Sponsored Risk Institutes -- 10. The Feldene Experience: A Case Study -- 11. Risk Perception of Prescription Drugs: Report on a Survey in Sweden -- 12. Risk Perception of Prescription Drugs: Report on Surveys in Japan -- 13. Scientific and Political Components of Regulatory Decision Making: General Considerations -- 14. Scientific and Political Components of Regulatory Decision Making: The United States Experience -- 15. Summary of Part II: Presentations and Discussions -- III: Current Challenges -- 16. Professional Drug Information: A Consumer Perspective -- 17. Going Patient, Going Public -- 18. Reporting Adverse Drug Reactions: The Media Approach -- 19. What Can Be Learned from Drug Safety Issues? -- 20. Summary of Part III: Presentations and Discussions -- IV: Responding to the Issues -- 21. Editor’s Note -- 22. Pharmacoepidemiology -- 23. Risk Perception Analysis -- 24. Communicating the Benefit/Risk Relationship -- 25. Risk Appraisal on an International Scale -- V: Outlook -- 26. The Wolfsberg Questions -- VI: Annex -- 27. Curriculum Vitae of Authors -- 28. Bibliography -- 29. Subject Index -- 30. A Handbook of International Data Sources for Drug Benefit/Risk Assessment.

There are no comments on this title.

to post a comment.

Powered by Koha